Recent applications of such treatments in CRC have been exemplified by the approval of oral kinase inhibitors or monoclonal antibodies, e.g., anti-angiogenesis (VEGF) and targeting epidermal growth factor receptor (EGFR). This evidence concerns the gene EGFR and colorectal carcinoma.